Compare Regeneron Pharmaceuticals Inc (REGN) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ventas Inc. Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $740.02 (market cap $76.14B), while Ventas Inc. Common Stock trades at $82.53 (market cap $41.94B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Ventas Inc. Common Stock pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Ventas Inc. Common Stock for 0 Days on average.
| REGN | VTR | |
|---|---|---|
Market Cap | $76.14B | $41.94B |
Volume | 500,239 | 4,588,793 |
Sector | Health | Real Estate |
52-Week High | $852.03 | $100.53 |
52-Week Low | $557.73 | $67.45 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $70.85B | $54.66B |
Dividend Yield | 0.51% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
